Maria Rodebaugh, MD
Endocrinology, Diabetes & Metabolism · Coeur D Alene, IDNPI 1114961190
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $406 and has fallen 70.4% since, to $120 in 2025.
Across 53 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$186
- Ascendis Pharma Endocrinology Inc$179
- Insulet Corporation$112
- Medtronic$111
- Tandem Diabetes Care, Inc.$95
- BETA Bionics, Inc.$60
- plus $447 from 13 others
What the payments were for
- Food & beverage$1,15697%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $186 |
| Ascendis Pharma Endocrinology Inc | 2 | $179 |
| Insulet Corporation | 5 | $112 |
| Medtronic(3 entities) | 5 | $111 |
| Tandem Diabetes Care, Inc. | 6 | $95 |
| BETA Bionics, Inc. | 2 | $60 |
| Lilly USA, LLC | 4 | $59 |
| Boehringer Ingelheim | 3 | $50 |
| Amgen(2 entities) | 3 | $50 |
| Recordati_rare_diseases_inc. | 1 | $46 |
| AstraZeneca | 3 | $44 |
| Antares Pharma, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Sequel Med Tech, LLC | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Pfizer | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$109
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 328 | $345,400 |
| OzempicSemaglutide | 316 | $344,082 |
| Somatuline DepotLanreotide Acetate | 20 | $171,851 |
| TrulicityDulaglutide | 107 | $138,808 |
| MounjaroTirzepatide | 73 | $113,048 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 18 | $95,679 |
| FarxigaDapagliflozin Propanediol | 89 | $92,790 |
| Teriparatide | 28 | $76,004 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $69,021 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $53,458 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $52,138 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $42,427 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 274 | $42,378 |
| Humalog Kwikpen U-100Insulin Lispro | 132 | $38,596 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $33,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $186 | $364,187370 claims |
| Boehringer IngelheimJardiance | $50 | $345,400328 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $59 | $270,771278 claims |
| AstraZenecaFarxiga | $44 | $92,79089 claims |
| Sanofi-aventis U.S. LLCLantus | $36 | $7,35157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Coeur D Alene
- Robert EnnisMeridian$69K
- Theodore RooseveltBoise$65K
- David LiljenquistIdaho Falls$9K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
- Richard ChristensenBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.